Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
| Autor: | Paolo Bonanni, Alessandro Rinaldi, M. Uhart, F Bianic, Francesco Saverio Mennini, Chiara De Waure, Giacomo Plazzotta, Gianluca Baio, Nathalie Largeron |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
HPV
medicine.medical_specialty Pediatrics Cost effectiveness Genital warts 03 medical and health sciences 0302 clinical medicine medicine Anal cancer 030212 general & internal medicine Settore SECS-P/01 - Economia Politica Cervical cancer Cost-effectiveness Italy Vaccination Gynecology lcsh:R5-920 business.industry Research Health Policy Gardasil Public health Cost-effectiveness analysis medicine.disease 030220 oncology & carcinogenesis lcsh:Medicine (General) business medicine.drug |
| Zdroj: | Cost Effectiveness and Resource Allocation, Vol 15, Iss 1, Pp 1-14 (2017) Cost Effectiveness and Resource Allocation : C/E |
| ISSN: | 1478-7547 |
| DOI: | 10.1186/s12962-017-0073-8 |
| Popis: | Background In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV positive cancers, over 80% of high-grade precancerous lesions and 90% of genital warts caused by HPV types 6/11. Methods A dynamic transmission model simulating the natural history of HPV-infections was calibrated to the Italian setting and used to estimate costs and QALYs associated with vaccination strategies. The analyses compared two strategies with the nine-valent vaccine (cervical cancer screening and vaccination in girls only or vaccination in boys and girls) to four alternative strategies (cervical cancer screening and vaccination with quadrialent vaccine in girls only, in both boys and girls, with bivalent vaccine in girls and screening strategy only). The National Health Service perspective was considered. Conclusion The switch to the nine-valent vaccine in Italy can further reduce the burden associated to cervical cancer and HPV-related diseases and is highly cost-effective. Results Compared to the current vaccination program with quadrivalent vaccine, the nine-valent vaccine in a programme including girls and boys shows further reductions of 17% in the incidence of cervical cancer, 35 and 14% in anal cancer for males and females, as well as over a million cases of genital warts avoided after 100 years. The new technology is associated with an ICER of 10,463€ per QALY gained in universal vaccination, decreasing to 4483€ when considering the vaccine switch for girls-only. Electronic supplementary material The online version of this article (doi:10.1186/s12962-017-0073-8) contains supplementary material, which is available to authorized users. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|